Background: Implantable cardioverter defibrillator (ICD) and cardiac resynchroniza-
| INTRODUCTION

Implantable cardioverter defibrillator (ICD) is an established therapy
for secondary prevention of sudden cardiac death (SCD) in patients with structural heart disease (SHD). [1] [2] [3] The rate of appropriate therapy by ICD insertion has been reported to be higher in patients in whom the device was implanted for secondary prevention than in␣patients in whom the device was implanted for primary prevention. [4] [5] [6] [7] [8] [9] [10] [11] Clinical trials on ICD therapy have been mainly conducted in European countries and the United States, where most cases of underlying heart disease are ischemic heart disease, [1] [2] [3] 5, [7] [8] [9] [10] [11] and thus, the findings may not be necessarily applicable to countries with different prevalences of heart diseases such as Japan, where SHD in 51%-69% of candidates for ICD therapy is cardiomyopathy. [12] [13] [14] [15] In the Japanese guidelines of ICD implantation for secondary prevention, 16 both documented ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in SHD are class I indication. However, it is unclear whether the rate of appropriate therapy differs depending on the type of prior ventricular arrhythmia or other clinical parameters. The aim of this study was to determine which clinical factors are associated with appropriate therapy in Japanese SHD patients in whom an ICD has been implanted.
| ME TH ODS
| Study subjects
We consecutively enrolled patients with SHD who underwent ICD or cardiac resynchronization therapy with defibrillator (CRT-D)
implantation between 1999 and 2015 at our institute for secondary prevention of SCD due to lethal ventricular arrhythmia. Lethal ventricular arrhythmia in this study was defined as resuscitated cardiopulmonary arrest (CPA), in most cases of which VF was documented, and/or sustained VT in patients with SHD. CPA was defined as ventricular arrhythmia resulting in loss of consciousness and requiring out-of-hospital cardiac resuscitation. Sustained VT was defined as VT requiring medical or external cardioversion for termination but being hemodynamically tolerable long enough for the patient to seek medical assistance. Patients in whom ventricular arrhythmias were associated with severe electrolyte imbalance, acute myocardial ischemia or proarrhythmic drug effects were excluded from this study. wave oversensing, or electrode dysfunction. When appropriate therapy was initially ATP and followed by shock because of failure of ATP to terminate the VT by ATP, the therapy was classified as ATP.
| Diagnosis of cardiovascular disease
Although detailed device programming was left to the discretion of treating electrophysiologists, we basically tried to detect as many ventricular arrhythmias as possible and we programmed the VT zone even in relatively lower heart rate, expecting effective therapy by ATP. Our basic ICD/CRT-D programming was as follows. In patients with cardiac arrest in whom VF was the only ventricular arrhythmia documented until the event of cardiac arrest, VF zone with a threshold of 320 ms was programmed. In patients with documented sustained VT, programming of the VT zone was set to a value of 40 ms below the clinically documented VT, and the VF zone was set to a value less than 320 ms. Even in patients with CPA, if frequent nonsustained VT was observed during follow-up period, VT zone was programmed. The primary endpoint of this study was the occurrence of first appropriate device therapy during the follow-up period. The secondary endpoint was first appropriate therapy or all-cause death.
Details of the pharmacological therapy were registered at the time of discharge after ICD/CRT-D implantation. 
| Statistical analysis
| RESULTS
The baseline characteristics of the study patients and comparison of clinical variables between the groups with and without episodes of appropriate ICD/CR-TD therapy during follow-up are shown in Table 1 . The study population consisted of 147 patients who underwent ICD (n = 136) or CRT-D (n = 11) implantation for secondary prevention of SCD. The mean age of the patients was 59 ± 15 years, and 73% of the patients were male. IHD accounted for 34% of the cases of SHD in the total study subjects. Reasons for device implantation were a prior history of sustained VT in 82 patients (56%) and history of CPA in 65 patients (44%). Mean LVEF was 45 ± 15%, and mean serum BNP level was 308 ± 399 pg/mL.
Seventy-nine patients (54%) had at least one appropriate ICD/CRT-D therapy during an average follow-up period of 3.2 ± 3.6 years.
When clinical variables were compared between the two groups with and without appropriate ICD/CRT-D therapy, the rate of sustained VT was higher (71% vs 38%, P < .001), the rate of CPA was lower (29% vs 62%, P < .001), LVEF was lower (42% vs 49%, P = .014), and left ventricular diameter was larger (57 mm vs 53 mm, P = .031) in the group with appropriate therapy than in the group without an episode of appropriate therapy. There was no significant difference in the rate of ischemic heart disease (49% vs 55%) or serum BNP level (291 pg/mL vs 328 pg/mL) between the two groups. Cardiac death occurred in 18 patients (heart failure in 13, sudden cardiac death in 4, and device lead infection in 1), and it was not associated with appropriate therapy. Data for the type of appropriate device therapy, that is, shock therapy or ATP, were available in 95% of patients. In patients with prior sustained VT who underwent appropriate therapy, 45 of 53 therapies (85%) were ATP.
On the other hand, ATP was performed only in 10 of 22 (46%) in patients with CPA (P = .001). In patients with CPA who did not undergo appropriate therapy, three cases had an episode of nonsustained VT which lasted more than 20 beats. Although these episodes were of therapy zone and not treated, they could have been treated if VT zone was programmed. Table 2 shows underlying cardiac diseases: old myocardial infarction (n = 50), dilated cardiomyopathy (n = 15), hypertrophic cardiomyopathy (n = 33), arrhythmogenic right ventricular cardiomyopathy (n = 10), cardiac sarcoidosis (n = 16), valvular heart disease (n = 11), other secondary cardiomyopathy (n = 9), tetralogy of fallot (n = 1), atrial septal defect post patch closure (n = 1), and left ventricular noncompaction (n = 1). There was no significant difference in etiology of SHD between the two groups with and without appropriate ICD/CRT-D therapy. At discharge, amiodarone, a beta-blocker, and class I antiarrhythmic drugs (AAD) were prescribed in 61%, 68%, and 29% (class Ib AAD accounted for 78% of class I AAD) of the patients, respectively ( Table 3) . The percentage of patients in whom amiodarone was prescribed was lower (53% vs 71%, P = .031), and the percentage of patients in whom class I AAD was prescribed was Figure 1A . Appropriate therapyfree rates were 68% at 1 year, 51% at 3 years, and 46% at 5 years.
Patients with sustained VT and those with CPA prior to ICD/CRT-D implantation showed different Kaplan-Meier curves. Appropriate therapy-free rates were 83% at 1 year, 72% at 3 years, and 66% at 5 years in patients with CPA and were 56% at 1 year, 34% at 3 years, and 30% at 5 years in patients with sustained VT (log-rank, P < .001). Kaplan-Meier curves for appropriate therapy-free rates in patients with IHD and those with SHD other than IHD were not significantly different (Figure 2) . A lower appropriate therapy-free rate in patients with prior sustained VT than in patients with CPA was found in subgroups of patients with and without IHD ( Figure 3A and␣3B). implantation for secondary prevention of SCD, but in most of those earlier studies conducted in Western countries, the underlying heart disease in the majority of patients was IHD. In a study by Borleffs et al, 8 the rates of appropriate ICD therapy were 52% at 5 years and 61% at 8 years after ICD implantation in patients with IHD. Similar results were reported by Schaer et al 9 for patients with heart diseases, 83% of whom had IHD and 17% of whom had cardiomyopathy. In their studies, the rates of appropriate ICD therapy were 59%
at 5 years and 65% at 10 years. In Japan, the proportion of patients with IHD in patients implanted with an ICD/CRT-D was reported to be 31%, and cardiomyopathy and valvular heart disease were etiologies of the heart disease in 66% and 3% of the patients, respectively. 13 In the present study, rates of appropriate ICD/CRT-D therapy were 49% at 3 years and 54% at 5 years (Figure 1 ), and the rates are similar to the rates in earlier studies despite the difference in the proportion of patients with IHD in the study subjects. [8] [9] [10] [11] It is notable that there was no significant difference between the rates of appropriate therapy in patients with IHD and patients with non-IHD SHD in the present study ( Figure 2 ). Taken together, the findings suggest that the rate of appropriate ICD/CRT-D therapy for secondary prevention of SCD in Japanese patients is comparable with the rates in the other ethnic groups and that IHD and cardiomyopathy in ICD/CRT-D therapy recipients have similar impacts on the rate of appropriate therapy. 
T A B L E 2 Underlying heart disease
| Comparison of rates of appropriate therapy in patients with ischemic and nonischemic cardiomyopathy
ICD therapy is effective for primary prevention and secondary prevention of SCD in patients with ischemic heart disease. F I G U R E 1 A, Kaplan-Meier survival curve for being free from appropriate ICD/CRT-D therapy. The cumulative probabilities for being free from appropriate ICD/CRT-D therapy were 68% at 1 year, 51% at 3 years, and 46% at 5 years. B, Kaplan-Meier survival curve for being free from appropriate ICD/CRT-D therapy according to the presenting arrhythmia before implantation. The cumulative probabilities for being free from appropriate ICD/CRT-D therapy were 83% at 1 year, 72% at 3 years, and 66% at 5 years in patients with CPA and they were 56% at 1 year, 34% at 3 years, and 30% at 5 years in patients with sustained VT (P < .001) studies [18] [19] [20] are consistent with the results of the present study.
Darma et al 18 compared the rates of appropriate therapy in patients with ischemic heart disease and patients with nonischemic heart dis- 
| Study limitations
There are several limitations in this study. First, the possibility that 
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